| [1] |
Vivanco I,Sawyers CL.The phosphatidylinositol 3-kinase AKT pathway in human cancer[J]. Nat Rev Cancer,2002,2(7):489-501.
|
| [2] |
Knobbe CB,Lapin V,Suzuki A,et al.The roles of PTEN in development,physiology and tumorigenesis in mouse models:a tissue-by-tissue survey[J]. Oncogene,2008,27(41):5398-5415.
|
| [3] |
Zhang H,Bajraszewski N,Wu E,et al.PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR[J]. J Clin Invest,2007,117(3):730-738.
|
| [4] |
Carracedo A,Baselga J,Pandolfi PP.Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors[J]. Cell Cycle,2008,7(24):3805-3809.
|
| [5] |
McCubrey JA,Steelman LS,Chappell WH,et al.Roles of the Raf/MEK/ERK pathway in cell growth,malignant transformation and drug resistance[J]. Biochim Biophys Acta,2007,1773(8):1263-1284.
|
| [6] |
McCubrey JA,Steelman LS,Franklin RA,et al.Targeting the RAF/MEK/ERK,PI3K/AKT and p53 pathways in hematopoietic drug resistance[J]. Adv Enzyme Regul,2007,47:64-103.
|
| [7] |
Chang JY,Sehgal SN,Bansbach CC.FK506 and rapamycin:novel pharmacological probes of the immune response[J]. Trends Pharmacol Sci,1991,12(6):218-223.
|
| [8] |
Mi R,Ma J,Zhang D,et al.Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model[J]. J Genet Genomics,2009,36(6):355-361.
|
| [9] |
Maira SM,Stauffer F,Brueggen J,et al.Identification and characterization of NVP-BEZ235,a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity[J]. Mol Cancer Ther,2008,7(7):1851-1863.
|
| [10] |
Ma J,Meng Y,Kwiatkowski DJ,et al.Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade[J]. J Clin Invest,2010,120(1):103-114.
|
| [11] |
Zhao L,Wientjes MG,Au JL.Evaluation of combination chemotherapy:integration of nonlinear regression,curve shift,isobologram,and combination index analyses[J]. Clin Cancer Res,2004,10(23):7994-8004.
|
| [12] |
Ma L,Chen Z,Erdjument-Bromage H,et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis[J]. Cell,2005,121(2):179-193.
|
| [13] |
Tang LL,Yokoyama Y,Wan X,et al.PTEN sensitizes epidermal growth factor-mediated proliferation in endometrial carcinoma cells[J]. Oncol Rep,2006,15(4):855-859.
|
| [14] |
Davies SP,Reddy H,Caivano M,et al.Specificity and mechanism of action of some commonly used protein kinase inhibitors[J]. Biochem J,2000,351(Pt 1):95-105.
|
| [15] |
Schnell CR,Stauffer F,Allegrinip R,et al.Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature:implications for clinical imaging[J]. Cancer Res,2008,68(16):6598-6607.
|
Acta Academiae Medicinae Sinica
